Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Otsuka In-licenses Asian Rights to Cancer Drug from Ariad for $77.5 Million

publication date: Dec 26, 2014
Otsuka Pharma of Japan snagged marketing rights to Iclusig® (ponatinib), a leukemia drug developed by Ariad Pharma, for Japan, China and eight other Asian countries. Otsuka will pay $77.5 million upfront plus additional regulatory milestones, and it agreed to fund clinical trials for the drug, except for the Japanese trial that is already underway. Ariad will receive a "substantial" share of net product revenues. Iclusig, a tyrosine kinase inhibitor, is designed to be effective in chronic myeloid leukemia with the T315I mutation, which is resistant to other approved therapies. More details....

Stock Symbols: (TYO: 4768) (NSDQ: ARIA)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital